-transparent.png){kind=logo}
Auranofin, an oral chrysotherapeutic agent, administered at 3.0 mg. b.i.d., p.o. to eight rheumatoid arthritic patients produced improvement in objective and subjective clinical signs, as well as biochemical and immunological parameters. Adverse effects reported were minimal and generally limited to gastrointestinal disturbances. During auranofin administration, gold concentrations in the blood gradually increased to a mean level of 0.70 microgram Au/ml by week 12 of treatment. Daily oral administration of auranofin appears to provide constant blood gold levels over longer periods of time compared to existing parenteral gold therapy and may provide an improved method of controlling chrysotherapy in rheumatoid arthritic patients.
F E Berglöf, and
K Berglöf, and
D T Walz
January 1984,
Clinical pharmacy,
F E Berglöf, and
K Berglöf, and
D T Walz
February 1984,
Seminars in arthritis and rheumatism,
F E Berglöf, and
K Berglöf, and
D T Walz
September 1984,
The Journal of allergy and clinical immunology,
F E Berglöf, and
K Berglöf, and
D T Walz
June 1976,
Annals of the rheumatic diseases,
F E Berglöf, and
K Berglöf, and
D T Walz
November 1982,
Casopis lekaru ceskych,
F E Berglöf, and
K Berglöf, and
D T Walz
December 1983,
The American journal of medicine,
F E Berglöf, and
K Berglöf, and
D T Walz
September 1986,
The Journal of the Association of Physicians of India,
F E Berglöf, and
K Berglöf, and
D T Walz
January 1983,
The Journal of pediatrics,
F E Berglöf, and
K Berglöf, and
D T Walz
June 1985,
The Journal of rheumatology,
F E Berglöf, and
K Berglöf, and
D T Walz
October 1986,
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
